Restasis

(Cyclosporine ophthalmic emulsion)

Restasis

Drug updated on 10/23/2023

Dosage FormEmulsion (topical: 0.5 mg/mL)
Drug ClassCalcineurin inhibitor immunosuppressant
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Product Monograph / Prescribing Information

Document TitleYearSource
Restasis (cyclosporine ophthalmic emulsion) Prescribing Information.2017Allergan, Irvine, CA, U.S.A

Systematic Reviews / Meta-Analyses